219 related articles for article (PubMed ID: 21281241)
1. Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
Burbury K; Chew LP; Westerman D; Catalano A; Seymour JF
Leuk Lymphoma; 2011 Feb; 52(2):335-8. PubMed ID: 21281241
[No Abstract] [Full Text] [Related]
2. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
3. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
4. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
5. [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib].
Fujimi A; Kanisawa Y; Kikuchi S; Okuda T; Sato Y; Doi T; Ohta H; Umeda I; Nobuoka A
Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2794-7. PubMed ID: 18203417
[No Abstract] [Full Text] [Related]
6. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
7. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
8. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
9. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
Jain N; Khoury JD; Pemmaraju N; Kollipara P; Kantarjian H; Verstovsek S
Blood; 2013 Nov; 122(19):3387-8. PubMed ID: 24203930
[No Abstract] [Full Text] [Related]
10. The hypereosinophilic syndrome: idiopathic or not, that is the question.
Cools J
Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
[No Abstract] [Full Text] [Related]
11. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
[No Abstract] [Full Text] [Related]
12. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
Srinivas U; Barwad A; Pubbaraju SV
Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
[No Abstract] [Full Text] [Related]
13. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
[No Abstract] [Full Text] [Related]
14. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
Winter L; Zellweger MJ; Bremerich J
Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
[No Abstract] [Full Text] [Related]
15. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
16. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
17. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
19. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
Tanaka H; Iwato K; Asou H; Kimura A
Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
[TBL] [Abstract][Full Text] [Related]
20. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
